StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a report released on Monday morning. The firm issued a hold rating on the biotechnology company’s stock.
Pulmatrix Stock Performance
NASDAQ PULM opened at $2.35 on Monday. The firm’s 50 day moving average price is $1.99 and its 200-day moving average price is $1.91. Pulmatrix has a 52-week low of $1.55 and a 52-week high of $2.73. The company has a market cap of $8.58 million, a PE ratio of -0.98 and a beta of 0.99.
Pulmatrix (NASDAQ:PULM – Get Free Report) last released its quarterly earnings data on Friday, May 10th. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter. Pulmatrix had a negative net margin of 75.73% and a negative return on equity of 44.05%. The firm had revenue of $5.89 million for the quarter.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Read More
- Five stocks we like better than Pulmatrix
- What is Short Interest? How to Use It
- First Solar Stock: The Dawn of a New Rally in Share Prices
- What is the Nikkei 225 index?
- Mastercard Stock’s Q2 Financial Results Outshine Competitors
- What Are Dividends? Buy the Best Dividend Stocks
- Tobacco Giant’s Shares Fall on EPS Miss, Lackluster Pouch Gains
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
